Clinical Trials in Boston

Showing 5901-5920 of 13,548 trials

Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle

NCT03079401

Patients under the age of 5, with a diagnosis of hypoplastic left heart syndrome (HLHS), unbalanced atrioventricular canal (uAVC), or borderline left heart who are undergoing staged LV recruitment following bidirectional Glenn (BDG) or undergoing BDG with plans for LV recruitment will be considered for enrollment in this study. Those patients enrolled in the study will be randomized to either the experimental arm or control arm of the study. Those patients randomized to the experimental arm will receive mesenchymal precursor cells (MPCs) injected directly into the LV endocardium during their LV recruitment or BDG procedure. Those patients randomized to the control arm will receive normal standard of care during their procedure with no injection of MPCs. It is believed that injection of MPCs will help improve the chances of those patients with single ventricle or borderline left ventricle being converted to biventricular circulation which could improve quality of life and longevity over palliation.

Hypoplastic Left Heart SyndromeAtrioventricular Canal

Boston Children's Hospital19 participantsStarted Nov 2017

Boston, Massachusetts, United States

COMPLETEDPhase 3< 1 mile

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia

NCT03416179

Glasdegib is being studied in combination with azacitidine for the treatment of adult patients with previously untreated acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy (Non-intensive AML population). Glasdegib is being studied in combination with cytarabine and daunorubicin for the treatment of adult patients with previously untreated acute myeloid leukemia (Intensive AML population).

Leukemia, Myeloid, Acute

Pfizer730 participantsStarted Apr 2018

Los Angeles, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +146 more locations

Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia

Find Trials by Condition in Boston

Genomic Response Analysis of Heart Failure Therapy in African Americans

Trauma Informed Intervention to Support Engagement in HIV Care Among MSM (THRIVE+)

A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

The Effect of Fontan Fenestration Closure on Hepatic Stiffness

A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer

Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures

Step Into Support for Endurance and Strength (SISTERS)

Using Machine Learning to Optimize User Engagement and Clinical Response to Digital Mental Health Interventions

Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Transcutaneous Spinal Cord Neuromodulation to Normalize Autonomic Phenotypes

Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)

Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)

Novel Use of Restasis and PROSE Devices

Evaluation of a Daily Disposable Silicone Hydrogel Multifocal Contact Lens in Myopes and Hyperopes

Thrombosomes® in Bleeding Thrombocytopenic Patients

A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)

VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)